{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"une-etude-sur-le-plx8394-en-monotherapie-chez-des-patients-atteints-de-tumeurs-solides-avancees-inoperables","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/fr\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"\u00c9tude sur le PLX8394 en monoth\u00e9rapie chez des patients atteints de tumeurs solides avanc\u00e9es et inop\u00e9rables"},"content":{"rendered":"<p><strong>Objectif de l'\u00e9tude :<\/strong>&nbsp; L'objectif de cette \u00e9tude clinique est de d\u00e9terminer comment le PLX8394 peut agir sur les cellules canc\u00e9reuses pr\u00e9sentant des mutations du g\u00e8ne BRAF. Le PLX8394 est con\u00e7u pour bloquer les mutations du g\u00e8ne BRAF. Ces mutations peuvent \u00eatre \u00e0 l'origine d'un cancer et favoriser la croissance des cellules canc\u00e9reuses.\u00a0 En bloquant ces mutations, le m\u00e9dicament pourrait d\u00e9truire les cellules canc\u00e9reuses porteuses de la mutation et\/ou emp\u00eacher la tumeur de se d\u00e9velopper.<\/p>\n<p><strong>Parrain :<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Coordonn\u00e9es pour l'essai :<\/strong>&nbsp; Divya Sakamuri ; 1-713-745-3296 ; dsakamuri@mdanderson.org ou Filip Janku ; 713-563-1930 ; FJanku@mdanderson.org<\/p>\n<p><strong>Participation demand\u00e9e au patient :<\/strong>&nbsp; Patients atteints d'ECD \u00e2g\u00e9s de plus de 18 ans.<\/p>\n<p><strong>Centres connus acceptant des patients atteints d'ECD dans le cadre de l'essai :<\/strong>&nbsp; MD Anderson, Houston, Texas<\/p>\n<p><strong>Identifiant ClinicalTrials.gov :<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}